Ironwood Pharmaceuticals | IRWD - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Almirall EUR 517.4M 32K 2025-12
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amarin USD 51.48M 113K 2025-12
Ardelyx USD 120.12M 14.46M 2025-12
Astellas Pharma JPY 489.36B 52.69B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Charles River Laboratories USD 875.93M 42.48M 2026-03
Coherus Biosciences USD 51.83M 2.48M 2025-12
Emergent BioSolutions USD 555.9M 242.7M 2023-06
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
Incyte USD 5.62B 4.5B 2026-03
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
MacroGenics USD 21.2M 32.13M 2026-03
Moderna USD 1.78B 242M 2026-03
Myriad Genetics USD 212.8M 16.2M 2025-12
Pacira USD 172.75M 20.93M 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Takeda JPY 1.11T 85.29B 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12